Frank Torti compensation by year
Roivant Sciences Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $725,000 |
| Bonus | $8,428,000 |
| Stock awards | $109,338,796 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $4,808,770 |
| Total | $123,300,566 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Roivant Sciences Ltd. DEF 14A filed July 29, 2026, accession 0001140361-26-029955, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Roivant Sciences Ltd. filed document, accession 0001140361-26-029955. Every figure is read from that document and cited to the page and table it appears in. Filed July 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 7,700,490 | $213,303,573 | — |
| PSU | 4,199,510 | $116,326,427 | — |
| RSU | 1,469,237 | $40,697,865 | — |
| Option | 344,233 | — | $3.85 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Roivant Sciences Ltd.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
8 Form 4 lines since the FY2025 proxy (filed July 29, 2026)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-12 | Tax withholding | — | 12,800 | $41.85 | 12,306,950 |
| 2026-11-12 | Other | — | 329,550 | $40.36 | 12,382,243 |
| 2026-11-12 | Other | — | 62,493 | $41.13 | 12,319,750 |
| 2026-11-11 | Other | — | 151,293 | $42.01 | 12,711,793 |
| 2026-11-11 | Other | — | 240,755 | $41.63 | 12,863,086 |
| 2026-11-10 | Other | — | 218,369 | $41.13 | 13,103,841 |
| 2026-11-10 | Other | — | 173,683 | $40.43 | 13,322,210 |
| 2026-09-30 | Tax withholding | — | 40,309 | $36.57 | 13,495,893 |
The 8 most recent of 8 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Roivant Sciences’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Frank Torti · this page | President and Vant Chair | $123,300,566 |
| Eric Venker | President and Immunovant CEO | $24,400,210 |
| Richard Pulik | Chief Financial Officer | $4,190,602 |
| Matthew Gline | Chief Executive Officer | $3,096,190 |
| Mayukh Sukhatme | President and Chief Investment Officer | $1,276,655 |
The full Roivant Sciences compensation record
free company briefThis page is one person within Roivant Sciences's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Roivant Sciences proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Roivant Sciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.